一例生化复发前列腺癌患者18F-Piflufolastat PET/CT阴性而18F-Fluciclovine PET/CT阳性
一例83岁前列腺癌患者外照射放疗后出现生化复发(PSA 29.7 ng/mL),18F-Piflufolastat PET/CT未见摄取病灶,因PSA高且高度怀疑复发而行18F-Fluciclovine PET/CT,检出15处盆腔、腹部、膈脚后及左锁骨上淋巴结转移。
要点
- 前列腺癌转移灶多数对PSMA靶向PET摄取,但部分转移灶不摄取。
- PSMA靶向PET阴性而PSA高时,代谢示踪剂如18F-Fluciclovine PET可定位并定量病变范围。
- 本病例中18F-Fluciclovine PET/CT检出15处淋巴结转移。
核心结论
- 尽管大多数前列腺癌转移灶对PSMA靶向PET摄取,但部分转移灶不摄取。
- 本病例表明,对于PSMA靶向PET不摄取转移灶的患者,18F-Fluciclovine PET等代谢示踪剂可定位并定量病变范围。
研究设计与样本
- 病例报告:一例83岁前列腺癌患者,外照射放疗后出现生化复发。
主要发现
- 患者PSA为29.7 ng/mL,18F-Piflufolastat PET/CT未见摄取病灶。
- 因PSA高且高度怀疑复发,行18F-Fluciclovine PET/CT,检出15处盆腔、腹部、膈脚后及左锁骨上淋巴结转移。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
An 83-year-old man with prostate cancer post external beam radiotherapy presented with biochemical recurrence (PSA, 29.7 ng/mL). PSMA-targeted 18 F-Piflufolastat PET/CT was performed, but no avid lesions were identified. Given the high PSA and high suspicion for recurrence, an 18 F-Fluciclovine PET/CT was performed. Fifteen 18 F-fluciclovine-avid pelvic, abdominal, retrocrural, and left supraclavicular nodal metastases were then identified. Although the majority of prostate cancer metastases are avid on PSMA-targeted PET, some metastases are not. This case demonstrates the ability of metabolic tracers such as 18 F-Fluciclovine PET to localize and quantitate disease extent in a patient whose metastases are not avid on PSMA-targeted PET.
引用
- Ulaner GA. Negative 18 F-Piflufolastat PET/CT, But Positive 18 F-Fluciclovine PET/CT, in a Patient With Biochemically Recurrent Prostate Cancer. Clin Nucl Med. 2024. PMID: 38693630. doi:10.1097/RLU.0000000000005243
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。